TDNet Discover

Background: Globally, depression is the most prevalent mental disorder that is associated with significant health and economic impacts. Common depression treatments include Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Selective Serotonin Reuptake Inhibitors (SSRIs). Problem: The current depression treatment, comprising SNRIs and SSRIs, often require considerable time to exhibit significant improvements and may not be universally effective. The purpose of this project was to compare the effectiveness of the Beck’s Depression Inventory -II (BDI-II) and the Patient Health Questionnaire -9 (PHQ-9) tools in evaluating the reduction of depression symptoms in patients undergoing low-dose ketamine treatment. Methods: A quantitative methodology with pre-post test design was used. Data was collected using PHQ-9 and BDI-II before and nine weeks after the implementation of the intervention. Intervention: BDI-II and PHQ-9 were used to measure the changes in patients’ depressive symptoms after treatment with low-dose ketamine. Results: There was a strong, statistically significant positive correlation coefficient of 0. 75289 between BDI-II and PHQ-9 scores. The mean decreases in depression severity between week 1 and week 9 for PHQ-9 and BDI-II tools were 0.85 and 7.03 respectively. There was a higher percentage decrease in BDI-II scores (23.2%) after the implementation of the intervention than PHQ-9 (6.4%). Conclusions: The results of this project indicates that BDI-II tool was more sensitive in capturing the changes in depressive symptoms than PHQ-9 after the implementation of the intervention.